Coherus BioSciences lays off 20% of staff, while antimicrobial biotech makes deeper cuts
More layoffs have hit the biotech industry this week, with Coherus BioSciences saying it let go about 60 employees and an antimicrobial drug developer parting ways with 30% of its staff.
The layoffs at Coherus, an immuno-oncology biotech and maker of biosimilars, equate to roughly 20% of the 359 full-time and part-time employees it had at the end of 2022, all based in the US. The Redwood City, CA biotech disclosed the news in its quarterly update. In an SEC filing, Coherus said most of the layoffs would go into effect on Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.